Sutro Biopharma, Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the results of the 2026 Annual Meeting of Stockholders held on June 5, 2026. Sutro Biopharma, Inc. (STRO) is a Delaware corporation with principal executive offices in South San Francisco, California.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
Three proposals were submitted to and adopted by security holders:
- Election of Directors: Three Class II directors were elected to three-year terms expiring at the 2029 Annual Meeting.
- Jane Chung: 11,355,214 shares For; 3,596 shares Withheld.
- Connie Matsui: 9,734,802 shares For; 1,624,008 shares Withheld.
- James Panek: 9,706,422 shares For; 1,652,388 shares Withheld.
- Ratification of Auditors: Ernst & Young LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
- 13,893,289 shares For; 501 shares Against; 5,883 shares Abstaining.
- Executive Compensation: Non-binding advisory approval of named executive officer compensation.
- 11,329,946 shares For; 22,412 shares Against; 6,452 shares Abstaining.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Investor Verification Checklist
- Verify the specific terms of the three-year directorships for Jane Chung, Connie Matsui, and James Panek.
- Confirm the engagement letter details with Ernst & Young LLP for the 2026 fiscal year.
- Review the full proxy statement for details on the executive compensation package approved by shareholders.
- Note the significant number of broker non-votes (2,540,863) recorded for the director elections and executive compensation proposal.